IP Library Granted Patent US 9,381,273
Granted Patent B2
US 9,381,273 · App. 12/320,594 · Granted Jul 5, 2016

Scaffolds with oxygen carriers, and their use in tissue regeneration

Inventors: Dan Gazit (Maccabim, IL); Gadi Pelled (Rishon-LeZion, IL); Zulma Gazit (Maccabim, IL); Nadav Kimelman-Bleich (Jerusalem, IL)
Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
A61L27/3843A61L27/225A61L27/3604A61L27/3834A61L27/52A61L27/56
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,381,273
App. No.
12/320,594
Granted
Jul 5, 2016
Kind
B2
Abstract

Provided are fibrin or silk matrices comprising an oxygen carrier, and matrices, which comprise an oxygen carrier and mesenchymal stem cells. Also provided are methods of generating and using same for ex vivo or in vivo tissue regeneration and/or repair such as for treating a non-union bone fracture and a condition requiring spinal fusion.

Claims (20)

1. A method of inducing in vivo cartilage tissue regeneration and/or repair, comprising implanting a matrix in cartilage of a subject in need thereof, said matrix comprising a protein backbone, mesenchymal stem cells and an oxygen carrier, wherein said oxygen carrier is selected from the group consisting of a hemoglobin molecule, a hemoglobin molecule derivative and a perfluorocarbon molecule and wherein the subject suffers from or is diagnosed with a pathology selected from the group consisting of loss of cartilage, injured cartilage, osteoarthritis, diseased intervertabral disc tissue, loss of intervertebral disc tissue, injured intervertebral disc tissue, articular cartilage defect,

thereby inducing the cartilage tissue regeneration and/or repair in said subject.

2. The method of claim 1 , wherein said cells are embedded within said matrix.

3. The method of claim 1 , wherein said backbone is made of a biodegradable or a biocompatible molecule.

4. The method of claim 1 , wherein said protein backbone comprises a fibrin backbone or a silk backbone.

5. The method of claim 1 , wherein said oxygen carrier is embedded within said backbone so that said oxygen carrier is unable to flow through, in or on said backbone.

6. The method of claim 1 , wherein said perfluorocarbon molecule comprises perfluorotributylamine (PFTBA) molecule.

7. The method of claim 1 , wherein a concentration of said perfluorocarbon molecule in the matrix is at least about 1% weight per volume (w/v).

8. The method of claim 4 , wherein the matrix further comprises thrombin.

9. The method of claim 1 , wherein said protein backbone is selected from the group consisting of fibrinogen, silk, PEGylated fibrinogen, collagen, PEGylated collagen, fibronectin, PEGylated fibronectin, fibrin, gelatin, albumin, elastin, and chondroitin-6-sulfate.

10. The method of claim 1 , wherein said hemoglobin molecule derivative is selected from the group consisting of a crosslinked haemoglobin, polymerized haemoglobin and encapsulated haemoglobin.

11. The method of claim 1 , wherein said hemoglobin comprises a recombinant hemoglobin.

12. The method of claim 1 , wherein said cells are absorbed to said matrix.

13. The method of claim 1 , wherein said cells are immobilized within or on said matrix.

14. The method of claim 1 , wherein said matrix comprises a gel matrix.

15. The method of claim 1 , wherein said tissue is under hypoxia.

16. The method of claim 1 , wherein said perfluorocarbon molecule is selected from the group consisting of perfluorooctylbromide molecule, octafluoropropane molecule, perfluorohexane molecule, perfluorodecalin molecule, perfluorodichlorooctane molecule, perfluorodecane molecule, perfluorotripropylamine molecule, perfluorotrimethylcyclohexane molecule, perfluoroperhydrophenanthrene molecule, perfluoromethyladamantane molecule, perfluorodimethyladamantane molecule, perfluoromethyldecaline molecule, perfluorofluorene molecule, diphenyldimethylsiloxane molecule, hydrogen-rich monohydroperfluorooctane molecule, and alumina-treated perfluorooctane molecule.

17. The method of claim 1 , wherein said perfluorocarbon molecule comprises perfluorodecalin molecule.

18. The method of claim 1 , wherein said cells are genetically modified.

19. The method of claim 18 , wherein said cells exogenously express morphogenetic proteins (BMP).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2009
From: GAZIT, DAN; PELLED, GADI; GAZIT, ZULMA; KIMELMAN-BLEICH, NADAV
To: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM
Reel/Frame 022743/0399 →
Continuity (2)
Provisional Application 61025135 · Jan 31, 2008
Related Publication 20090214649A1 · Aug 27, 2009